Healwell AI Posts Record Revenue and Turns EBITDA Positive, Yet the Stock Keeps Falling

Healwell AI's Q1 revenue soared 316% to C$33.2M with positive adjusted EBITDA, yet shares hit near 52-week lows. Investors question sustainability as international AI expansion and a SpaceX stake offer mixed signals.

Healwell AI delivered what would normally be a headline-grabbing quarter: revenue surged 316% to 33.2 million Canadian dollars in the first quarter of 2026, and adjusted EBITDA swung from a loss of 2.3 million to a gain of 0.7 million. Yet the market’s response has been anything but celebratory. The stock slipped another 2.92% on the day of the release, and the broader trend is even starker — shares have shed 25.94% since the start of the year, now trading at €0.415, a staggering 60.44% below the 52-week high of €1.05 set last August.

The disconnect between operational momentum and share price performance has left investors scratching their heads. On one hand, the Canadian healthcare software company has successfully pivoted from an acquisition-heavy strategy to a pure-play SaaS and AI business model. The integration of Orion Health is complete, non-core clinical divisions were sold off earlier this spring, and the company’s annual general meeting has formally ratified the transformation. On the other hand, the stock is flirting with its 52-week low of €0.3644, just 7.71% above that floor.

The Profitability Puzzle

The central question hanging over Healwell is whether its newly achieved adjusted EBITDA can be sustained and scaled. The first-quarter figure of 0.7 million Canadian dollars marks a genuine inflection point, but the company’s IFRS net loss — while narrowing from 14.1 million to 6.8 million Canadian dollars year-over-year — underscores how far the business remains from true profitability. Global integration costs and ongoing R&D spending continue to weigh on the bottom line.

Management has set an ambitious target: a 10% adjusted EBITDA margin by the end of 2026. The next major checkpoint comes in August, when second-quarter results will reveal whether the first quarter’s profitability was a one-off or the start of a durable trend.

DARWEN and the International Push

The linchpin of Healwell’s growth story is DARWEN, its AI-powered clinical decision-support platform marketed under the “SMART” brand. A multi-province pilot project in Canada recently confirmed that the platform reduces chart review workload and improves clinical workflows. Those results will be presented at the AMIA 2026 Annual Symposium in November, offering a qualitative validation point for investors.

More immediately, Healwell is expanding beyond Canadian borders. The company secured a multi-million-dollar contract for a Health Information Exchange in the United States, and its first AI deployment in the Middle East is already underway. These international wins are critical to demonstrating that DARWEN can compete commercially outside its home market.

The SpaceX Wild Card

One unusual asset sits on Healwell’s balance sheet: an indirect stake in SpaceX, valued at approximately 25 million Canadian dollars. The position originated from the company’s earlier acquisition of xAI, which was completed in February 2026. While the shares are currently subject to a lock-up period following SpaceX’s IPO, management views the holding as a strategic buffer that could eventually be monetized to fund the core AI business.

Technical Signals and Market Sentiment

From a technical perspective, the stock is deeply oversold. The 14-day RSI stands at 30.9 — one source puts it even lower at 25.9 — and shares trade 29.66% below their 200-day moving average of €0.5580. Such readings often precede sharp reversals if positive catalysts emerge. However, the stock has yet to reclaim its 50-day moving average of €0.4929, a level that could act as a near-term resistance point.

The market’s caution may also reflect structural concerns. Healwell’s customer access runs through the WELL Health ecosystem, a dependency that could cap its valuation relative to independent global SaaS peers. And while the adjusted EBITDA improvement is encouraging, the gap between that measure and the IFRS net loss leaves room for skepticism.

What’s Next

The second-quarter report in August will be the most immediate test of whether Healwell’s margin trajectory is on track. A miss on the 10% EBITDA margin goal could send the stock testing its 52-week low again. Conversely, any positive surprise — particularly on organic revenue growth or cost containment — could trigger a technical bounce given the oversold conditions.

Beyond the numbers, the November AMIA symposium will provide a qualitative read on DARWEN’s commercial scalability. For now, Healwell remains a story of operational progress colliding with market doubt, with the next few months set to determine which force wins out.